Beyond cisplatin: New frontiers in metallodrugs for hard-to-treat triple negative breast cancer

Heterocyclic (pyrazine)carboxamide Ru(ii) complexes: structural, experimental and theoretical studies of interactions with biomolecules and cytotoxicity

“…Platinum group metals primarily exert their mode of action by binding to the DNA molecule, thereby impeding the synthesis and replication processes. 41–43 This interference ultimately leads to cell death. 44 DNA titration experiments help in understanding how molecules interact with DNA, which is crucial in various biological processes such as gene regulation, DNA replication, and repair.…”

Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound

“…16 Ruthenium(II) compounds specifically display high activity against cisplatin-resistant and metastasized tumors by a mode of action that differs from that of cisplatin (e.g., DNA does not seem the main biological target). 13 We have previously reported on a water-soluble, cationic, organometallic Ru(II) compound [(η 6 1A), that contains an arene, a labile chloro, and a chelating N−O iminophosphorane ligand. 17,18 Ru-IM displays relevant anticancer activity and a favorable pharmacological profile that makes it highly attractive as a potential TNBC chemotherapeutic.…”

“…Moreover, patients with BRCA mutated genes and some with specific TNBC subtypes unresponsive to anthracycline-taxane (ACT) seem to benefit from the use of these platinum agents . Metallodrugs based on unconventional platinum compounds, and derivatives of metals other than platinum such as gold and ruthenium, have displayed relevant anticancer properties in TNBC cells and mouse models. , Three ruthenium-based compounds have been studied in the clinic for different cancers: two ruthenium­(III) compounds NAMI-A (used in phase II trials for the treatment of nonsmall cell lung cancer), and BOLD-100 (currently in phase II trials for the treatment of advanced gastrointestinal cancers) and a ruthenium­(II) derivative TLD-1433 (a photodynamic therapy currently in phase trials for the treatment of nonmuscle invasive bladder cancer) . Ruthenium­(II) compounds specifically display high activity against cisplatin-resistant and metastasized tumors by a mode of action that differs from that of cisplatin (e.g., DNA does not seem the main biological target) …”

Copper(II) Complexes with 1-(Isoquinolin-3-yl)heteroalkyl-2-ones: Synthesis, Structure and Evaluation of Anticancer, Antimicrobial and Antioxidant Potential

“…Consequently, with the emergence of many biomedical applications of other transition metal complexes, including anticancer and antimicrobial agents, attention is shifting beyond platinum-based compounds [ 1 , 8 , 9 , 10 , 11 ]. The preclinical studies provide evidence that non-platinum agents have the potential to circumvent the problem of chemoresistance and the toxicity of platinum-based agents by exhibiting different specific modes of action, reduced undesirable effects and the ability to overcome drug-resistance mechanisms [ 10 , 12 , 13 ].…”

“…), 9.12 (s, 1H, CH 1 -isoquin. );13 C-NMR (DMSO-d 6 , 100 MHz) δ (ppm): 12.81, 38.40, 40.97, 41.77, 105.36, 125.19, 125.39, 126.50, 127.96, 131.11, 137.53, 148.63, 151.11, 157.00; MS (ESI, CH 3 OH:CH 3 CN+0,1% CH 3 COOH, 1:1, v/v) m/z = 242 [M+H] + , m/z = 264 [M + Na] + , and m/z = 305 [M + Na + CH 3 CN] + . Calculated for C 14 H 15 N 3 O (241.29): C, 69.69; H, 6.27; N, 17.41.…”